TY - JOUR AU - Drzewiecka-Jędrzejczyk, Magdalena AU - Wlazeł, Rafał AU - Terlecka, Monika AU - Jabłoński, Sławomir PY - 2017 TI - Serum metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in lung carcinoma patients JF - Journal of Thoracic Disease; Vol 9, No 12 (December 29, 2017): Journal of Thoracic Disease Y2 - 2017 KW - N2 - Background: Assessment of serum extracellular matrix (ECM) metalloproteinase MMP-2 and tissue inhibitor of matrix metalloproteinase TIMP-2 concentrations in non-small cell lung carcinoma (NSCLC) patients considering TNM staging. Assessment of the prognostic value of MMP-2 and TIMP-2 concentrations in NSCLC patients. Methods: The study group consisted of 81 NSCLC patients (24 females and 57 males) aged 46 to 86 years (mean age of 67±8.2 years). The control group comprised 39 randomly selected patients (20 females and 19 males) aged 27 to 73 years (mean age of 47±15.0 years) in whom primary lung cancer was excluded and who were operated on for a calculus of the gallbladder without cholecystitis. Blood serum MMP-2 and TIMP-2 concentrations were determined using an enzyme-linked immunosorbent assay (ELISA)-based test. Results: Statistically significantly higher mean MMP-2 and TIMP-2 concentrations were found in NSCLC patients compared to those in the control group (P Conclusions: Serum MMP-2 and TIMP-2 concentrations in NSCLC patients correlated with the tumour size and presence of metastases to lymph nodes and thus may serve as an auxiliary parameter indicating probability of a more advanced stage of lung cancer. UR - https://jtd.amegroups.org/article/view/17832